Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10311690 | 0.89 | ALDH1A1 (0.55) | GAAALDH1A1MAPK1CHRNB2CHRNA3 | |
| SCHEMBL4546658 | 0.89 | GAA (0.53) | GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL3400414 | 0.87 | GAA (0.45) | GAAALDH1A1MAPK1SMN1; SMN2LMNA | |
| SCHEMBL20385047 | 0.87 | GAA (0.45) | GAAALDH1A1MAPK1SMN1; SMN2LMNA | |
| SCHEMBL12233572 | 0.83 | XPNPEP2 (0.45) | ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL17636777 | 0.83 | CHRNB2 (0.44) | ALDH1A1SMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL3283616 | 0.83 | XPNPEP2 (0.45) | ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL23119140 | 0.83 | EPHX2 (0.51) | GAAALDH1A1MAPK1SMN1; SMN2LMNA | |
| SCHEMBL20438070 | 0.79 | SMN1; SMN2 (0.54) | GAAALDH1A1SMN1; SMN2CHRNB2CHRNA3 | |
| SCHEMBL14348122 | 0.79 | SMN1; SMN2 (0.54) | GAAALDH1A1SMN1; SMN2CHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-9725448-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | GAA 125/4885ALDH1A1 2644/4885MAPK1 1373/4885 |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GAA 125/4885ALDH1A1 2644/4885MAPK1 1373/4885 |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | GAA 176/4885ALDH1A1 3379/4885MAPK1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.